Anti-RAD9A antibody produced in rabbit
SIGMA/HPA006725 - Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Synonym: Anti-Cell cycle checkpoint control protein RAD9A; Anti-DNA repair exonuclease rad9 homolog A; Anti-hRAD9
Product Type: Chemical
Enhanced Validation-Orthogonal RNAseq Confirmation Immunohistochemistry analysis in human small intestine and liver tissues using Anti-RAD9A antibody. Corresponding RAD9A RNA-seq data are presented for the same tissues.
By Recombinant Expression Western Blotting. Western blot analysis in control (vector only transfected HEK293T lysate) and RAD9A over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY401451).
Immunohistochemistry Immunohistochemical staining of human liver shows low expression as expected.
Immunohistochemistry Immunohistochemical staining of human small intestine shows high expression.
Immunofluorescence Immunofluorescent staining of human cell line U-251 MG shows localization to nucleoplasm.
Prestige Antibodies® Highly characterized and Enhanced Validated antibodies
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| conjugate | unconjugated |
| enhanced validation | recombinant expression orthogonal RNAseq Learn more about Antibody Enhanced Validation  |
| form | buffered aqueous glycerol solution |
| immunogen sequence | AIFTIKDSLLDGHFVLATLSDTDSH |
| product line | Prestige Antibodies® Powered by Atlas Antibodies |
| Quality Level | 100 |
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunofluorescence: 0.25-2 μg/mL |
| immunohistochemistry: 1:200-1:500 | |
| western blot: 0.04-0.4 μg/mL | |
| UniProt accession no. | Q99638  |
| Application: | All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies® protocols and other useful information. |
| Biochem/physiol Actions: | RAD9A is a member of Rad family of checkpoint proteins localized at the nuclease active site. It is highly involved in the initial stage of DNA damage checkpoint response and DNA replication. It forms a ternary complex with two other checkpoint Rad proteins, hRAD1, and hHUS1 for 3′ to 5′ exonuclease activity. The RAD9A exonuclease activity may have a contribution to the DNA damage checkpoint response in humans. It consists of a nuclear localization sequence (NLS) at the C-terminal end. The NLS region is essentially required for the nuclear transport of checkpoint complex protein, human RAD9, human Rad1 (hRad1) and human Hus1 (hHus1) into the nucleus. It controls the G(2) checkpoint by guiding the checkpoint complex proteins. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| Features and Benefits: | Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section. Every Prestige Antibody is tested in the following ways: • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. • Protein array of 364 human recombinant protein fragments. |
| Immunogen: | Cell cycle checkpoint control protein RAD9A recombinant protein epitope signature tag (PrEST) |
| Legal Information: | Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Other Notes: | Corresponding Antigen APREST71088 |
| Physical form: | Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |